Warm Autoimmune Hemolytic Anemia in Asymptomatic Patients with Hemoglobin ≥ 10 g/dL

Not every patient with warm autoimmune hemolytic anemia requires active treatment. When hemolysis is adequately compensated and the hemoglobin level remains at or above 10 g/dL, the clinical question shifts from what to treat to whether to treat — and how to monitor safely.

Clinical Scenario

Asymptomatic patients with minimal anemia whose hemolysis is sufficiently compensated — typically with a hemoglobin level of 10 g/dL or higher — may not require any active therapy. In this population, aggressive treatment may reduce quality of life without meaningful clinical benefit.

Management Approach

For these patients, the protocol favours close follow-up and targeted nutritional support over active immunosuppressive therapy. The full structured protocol specifies exactly what is recommended and under what circumstances escalation should be considered.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1182/hematology.2022000405

Some patients with minimal anemia are sufficiently compensated for their hemolysis and may not require any therapy.
Such asymptomatic patients usually have Hgb level higher than or equal to 10g/dL and might experience a reduced quality of life with therapy.
These patients are followed closely, supplemented with folate, and advised to contact their hematologist should they experience signs of worsening hemolysis (eg, darker urine, more icterus, worsening fatigue), especially when stressed by infection or other medical problems.

View source ↗